Novacap announced that it has signed an agreement to acquire Boston-based PCI Synthesis, a leading U.S. pharmaceutical contract development and manufacturing organization (CDMO), further reinforcing Novacap’s capabilities and offering for the pharmaceutical industry.
Novacap is a global player in pharmaceutical synthesis, advanced specialties and cosmetics. The Group offers its clients custom manufacturing services for pharmaceutical and speciality markets as well as a large portfolio of APIs & pharmaceutical intermediates.
PCI Synthesis is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, PCI Synthesis provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules.
The company operates a R&D facility in Devens (USA), and a manufacturing facility in Newburyport (USA), and generates a turnover of $32 million. Leveraging its wide business offering and technologies, proximity to customers, reactivity and undisputed project management skills, PCI Synthesis has achieved tremendous growth over the last years, most recently closing its fifth consecutive year-to-year of double-digit growth. This has been driven by more than forty new customers and an expansion into new offerings such as GMP manufacturing for nutraceuticals and pharma foods, large-scale chromatography, controlled substance development, and medical-grade polymers. The company is North America’s most awarded drug substance manufacturer and has become a strategic partner for the U.S. pharmaceutical and biotechnology industries.
The combination of the two companies will provide PCI Synthesis with additional resources to continue its development while reinforcing Novacap’s global leadership in pharmaceutical synthesis with 12 cGMP sites, 2 main R&D centers and its comprehensive range of services and technologies dedicated to clinical development and commercial manufacturing.
Novacap, headquartered in France, is a global player in pharmaceutical synthesis, advanced specialties and cosmetics. The Group offers its clients custom manufacturing services for pharmaceutical and speciality markets as well as a large portfolio of APIs & pharmaceutical intermediates. Novacap also boasts leading positions in a variety of markets, including cosmetics and fragrances, electronics, home care, food and feed or environment.